New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
05:55 EDTAON, AON, PRGO, PRGO, NWL, NWL, NOV, NOV, MRK, MRK, MAT, MAT, LYB, LYB, LM, LM, IR, IR, BEN, BEN, XOM, XOM, CVX, CVX, BEAM, BEAM, TSN, TSNCompanies reporting Before the Market Open on FridayFebruary 1
Notable companies reporting before the opening bell on Friday include Aon (AON), Beam (BEAM), Chevron (CVX), Exxon Mobil (XOM), Franklin Resources (BEN), Ingersoll-Rand (IR), Legg Mason (LM), LyondellBasell Industries (LYB), Mattel (MAT), Merck (MRK), National Oilwell Varco (NOV), Newell Rubbermaid (NWL), Perrigo (PRGO), and Tyson Foods (TSN).
News For AON;BEAM;CVX;XOM;BEN;IR;LM;LYB;MAT;MRK;NOV;NWL;PRGO;TSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 12, 2014
07:28 EDTLMBofA/Merrill to hold a conference
Subscribe for More Information
06:53 EDTTSNTyson Foods volatility elevated into Q4 and outlook
Subscribe for More Information
06:07 EDTLYBLyondellBasell authorizes 70c interim dividend
Subscribe for More Information
November 11, 2014
16:01 EDTMRKOptions Update; November 11, 2014
Subscribe for More Information
15:43 EDTMRKLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
09:37 EDTMRKActive equity options trading
Subscribe for More Information
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
07:47 EDTCVXJacobs Engineering receives contract from Chevron in South Africa
Subscribe for More Information
November 10, 2014
16:40 EDTBENFranklin Resources reports $898.4B under management at October 31
Subscribe for More Information
15:53 EDTPRGOCredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
15:51 EDTLYBMorgan Stanley to hold a conference
Subscribe for More Information
15:43 EDTCVXAmerican Petroleum Institute to hold a conference
Subscribe for More Information
12:09 EDTTSNUSDA raises 2014 meat production forecast, lowers 2015
Subscribe for More Information
09:20 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
07:19 EDTPRGOCredit Suisse to hold a conference
Subscribe for More Information
07:18 EDTCVXChevron hasn't finished shale gas assessment in Romania, Reuters reports
Subscribe for More Information
07:08 EDTLMCredit Suisse to hold a conference
2014 Boston Financials 1:1 Conference to be held in Boston on November 10-11.
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use